Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL799721 | 1.00 | FABP7 (0.46) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29710361 | 1.00 | FABP7 (0.46) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29516735 | 1.00 | FABP7 (0.46) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29401030 | 1.00 | FABP7 (0.46) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4362743 | 1.00 | FABP7 (0.46) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL800040 | 0.93 | SMN1; SMN2 (0.53) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29922193 | 0.93 | SMN1; SMN2 (0.53) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15884802 | 0.93 | SMN1; SMN2 (0.53) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1372951 | 0.89 | TSHR (0.43) | FABP7FABP5SMN1; SMN2NPC1RAB9A | |
| SCHEMBL4359233 | 0.89 | TSHR (0.43) | FABP7FABP5SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3515880-B1 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF ENCODED LIBRARIES | HITGEN INC (CN) | 2023-05-10 | — | — | EP | disclosed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | disclosed |
| CN-108698992-B | 2-cyanoisoindoline derivatives for the treatment of cancer | 特殊治疗有限公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3429994-B1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | MISSION THERAPEUTICS LTD (GB) | 2021-06-16 | — | — | EP | disclosed |
| US-10689415-B2 | Conjugates of RGD peptides and (bacterio)chlorophyll photosensitizers | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2020-06-23 | — | — | US | disclosed |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-16 | — | — | US | disclosed |
| US-10654834-B2 | Non-systemic TGR5 agonists | Venenum Biodesign, LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | Venenum Biodesign, LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-2061512-B1 | CONJUGATES OF RGD PEPTIDES AND (BACTERIO)CHLOROPHYLL PHOTOSENSITIZERS AND THEIR USES | YEDA RES & DEV (IL) | 2019-10-02 | — | — | EP | disclosed |
| EP-3429994-A1 | 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER | Mission Therapeutics Limited (GB) | 2019-01-23 | — | — | EP | disclosed |
| EP-0708765-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO. INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| CN-1119019-A | Compositions and methods for treating immunomodulatory inflammation | ARRIS PHARM CORP (US) | 1996-03-20 | — | — | CN | disclosed |
| EP-0688337-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1995-12-27 | — | — | EP | disclosed |
| WO-1995002587-A1 | SUBSTITUTED PIPERAZINYLCAMPHOR DERIVATIVES AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994020527-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNOMEDIATED INFLAMMATORY DISORDERS | ARRIS PHARMACEUTICAL CORPORATION (US) | 1994-09-15 | — | — | WO | disclosed |
| US-5204349-A | Treatment of preterm labor, dysmenorrhea and for stoppage of labor prior to cesarian delivery | MERCK & CO., INC. (US) | 1993-04-20 | — | — | US | disclosed |
| WO-1993006092-A1 | PIPERAZINYL (SULFONYL)AMIDE DERIVATIVES OF CAMPHOR AS OXYTOCIN ANTAGONISTS | MERCK & CO., INC. (US) | 1993-04-01 | — | — | WO | disclosed |
| CN-1070399-A | The amide derivatives oxytocin antagonist that piperizinylcamphorsuoxytocin replaces | MERCK & CO INC (US) | 1993-03-31 | — | — | CN | disclosed |
| EP-0533244-A1 | Amide-substituted derivatives of spiroindanylcamphorsulfonyl oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-24 | — | — | EP | disclosed |
| EP-0532097-A1 | Piperazinyl(sulfon)amide derivatives of camphor as oxytocin antagonists | MERCK & CO. INC. (US) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689415-B2 | Conjugates of RGD peptides and (bacterio)chlorophyll photosensitizers | MVD, AGER, FOLH1 | FABP7 738/4885FABP5 855/4885SMN1; SMN2 4811/4885 |
| US-20190330191-A1 | NOVEL NON-SYSTEMIC TGR5 AGONISTS | GPR119, FFAR1, FFAR3 | FABP7 515/4885FABP5 54/4885SMN1; SMN2 3965/4885 |
| US-10654834-B2 | Non-systemic TGR5 agonists | GPR119, SSTR5, FFAR3 | FABP7 653/4885FABP5 75/4885SMN1; SMN2 3817/4885 |
| US-10683269-B2 | 2-cyanoisoindoline derivatives for treating cancer | USP7, USP47, USP2 | FABP7 2979/4885FABP5 3195/4885SMN1; SMN2 4184/4885 |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | FABP7 4842/4885FABP5 4534/4885SMN1; SMN2 3236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.